Factors That Influence Fenofibrate Effects On Cancer Cells

A recent clinical trial for pediatric embryonal brain tumors reported encouraging results, with a treatment scheme that included peroxisome proliferator-activated receptor-α (PPARα) agonist fenofibrate [1]. The treatment scheme was aimed at inhibiting neovascularization; however, the drugs used can inhibit cancer cell growth by a number of mechanisms. In a different treatment scheme, aimed to treat a variety of recurrent or progressive tumors, fenofibrate could not demonstrate similarly encouraging effects [2]